Abstract 101P
Background
Deep molecular analysis with high throughput technology has improved the outcomes of advanced cancer patients. The molecular tumor board has a fundamental role in guiding treatment offering the evaluation of those molecular variants beside the ESCAT 1 level of evidence.
Methods
2010 patients diagnosed with solid tumors were prospectively analyzed in our institution with an extensive NGS panel. Patients were molecularly selected to receive a molecular-matched treatment according to international guidelines or to be enrolled in early phase trials, based on the evaluation of a single institution multidisciplinary molecular tumor board.
Results
1726 of 2010 (85.9%) patients presented any genomic or transcriptomic alterations. Of those, 1086 (62.9%) presented with advanced disease. 128 patients (11.8%) received standard targeted agents. 161 (14.8%) patients presented with druggable mutations beyond ESCAT 1 level such as BRAFnoV600, FGFR, NRAS, PIK3CA, ERBB2 and DNA repair genes, and BRAF fusions. Finally, 67 (6.1%) of those patients entered an early-phase clinical trial to receive a novel molecular-matched approach.
Conclusions
We demonstrate the pivotal role of the institutional molecular tumor board in evaluating the results of an extensive NGS panel. This process optimizes the selection of experimental novel molecular-matched therapies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
174P - Human adipose stem cells transfer their mitochondria to breast cancer patient derived organoids increasing drug resistance
Presenter: Martina Marigliano
Session: Cocktail & Poster Display session
Resources:
Abstract
175P - Differential impact of increased neoantigen load on PD-L1 positive immune cell infiltrations in comparison to PD-L1 expression on tumor cells
Presenter: Ashok Kumar Vaid
Session: Cocktail & Poster Display session
Resources:
Abstract
176P - Patient race is a determinant of the impact of Y chromosome loss on survival
Presenter: Suhyeon Choi
Session: Cocktail & Poster Display session
Resources:
Abstract
178P - Clinical correlates and impact of ctDNA levels on detecting distinct genomic alteration in patients with metastatic colorectal cancer
Presenter: Luca Boscolo Bielo
Session: Cocktail & Poster Display session
Resources:
Abstract
179P - Identification of guanine-quadruplex forming DNA aptamer: A promising therapeutic strategy for EGFR overexpressed non-small cell lung cancer
Presenter: Deepa Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
180P - Unravelling drug resistance in high-grade serous ovarian cancer through clonal dynamics and single-cell heterogeneity analysis
Presenter: Alvaro Ingles Russo Garces
Session: Cocktail & Poster Display session
Resources:
Abstract
181P - Establishment of primary prostate cancer patient-derived organoids to assess PARP inhibitors antitumor activity beyond synthetic lethality
Presenter: Tatiana P. Grazioso
Session: Cocktail & Poster Display session
Resources:
Abstract
182P - METHRO: Multicentric study of risk of thrombosis in patients with NSCLC harboring a METexon 14 skipping mutation
Presenter: Maria Virginia Sanchez Becerra
Session: Cocktail & Poster Display session
Resources:
Abstract
183P - SomaVar: A web application for somatic variant storage, annotation and classification
Presenter: Sorin Armeanu-Ebinger
Session: Cocktail & Poster Display session
Resources:
Abstract